サマリー

欧州の水頭症市場は、2023年の368,048,70千米ドルから2031年には577,379,08千米ドルに達し、2024年から2031年の予測期間において年平均成長率6.0％で成長すると予測されている。

市場セグメント
欧州水頭症市場：タイプ別（先天性水頭症、後天性水頭症、正常圧水頭症、外水頭症）、診断・治療別（診断と治療）、エンドユーザー別（病院、診療所、診断センター、学術機関・研究機関）、国別（ドイツ、英国、フランス、イタリア、スペイン、ロシア、オランダ、スイス、ベルギー、トルコ、アイルランド、その他欧州）-産業動向と2031年までの予測
欧州水頭症市場のダイナミクス

促進要因
- 神経疾患の発生率の増加
抑制要因

- 不十分な償還政策

機会

- 医療機関や政府機関による支援の拡大

市場プレイヤー

欧州の水頭症市場で事業を展開する主な市場参入企業は以下の通り：

- B. Braun傘下のAesculap, Inc.
- インテグラ・ライフサイエンス
- ジー・サーギウェア社
- モレール・メディカル社
- アヌンシア社
- クリストフ・ミースケGmbH & co.KG
- KARL STORZ SE & Co.KG
- 株式会社プロテテス
- メドトロニック
- ナタス
- デスーメディカル
- ビカクシラー
- シュピーゲルベルグGmbH & Co.KG
- ソフィサ
- カネカメディックス

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF EUROPE HYDROCEPHALUS MARKET 31
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 32
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 DBMR TRIPOD DATA VALIDATION MODEL 38
2.6 MULTIVARIATE MODELLING 41
2.7 TYPE LIFELINE CURVE 41
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.9 DBMR MARKET POSITION GRID 43
2.10 VENDOR SHARE ANALYSIS 44
2.11 SECONDARY SOURCES 45
2.12 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 48
5 EUROPE HYDROCEPHALUS MARKET: REGULATIONS 49
5.1 REGULATIONS IN U.S. 49
5.2 REGULATIONS IN EUROPE 49
5.3 REGULATIONS IN INDIA 49
5.4 REGULATIONS IN JAPAN 50
5.5 REGULATIONS IN BRAZIL 50
6 MARKET OVERVIEW 51
6.1 DRIVERS 53
6.1.1 INCREASING INCIDENCE OF NEUROLOGICAL CONDITIONS 53
6.1.2 GROWING NUMBER OF NEW-BORNS AFFECTED BY HYDROCEPHALUS 53
6.1.3 INCREASING ADAPTATION OF ADVANCED PROGRAMMABLE VALVES 54
6.1.4 RISING AWARENESS ABOUT HYDROCEPHALUS 54
 
6.2 RESTRAINTS 55
6.2.1 POOR REIMBURSEMENT POLICIES 55
6.2.2 DELETERIOUS COMPLICATIONS WITH HYDROCEPHALUS DEVICES 55
6.3 OPPORTUNITIES 56
6.3.1 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES 56
6.3.2 GROWING HEALTHCARE EXPENDITURE 57
6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 57
6.4 CHALLENGES 58
6.4.1 HIGH PRODUCT RECALL SCENARIO 58
6.4.2 LACK OF ACCESSIBILITY OF HYDROCEPHALUS PRODUCTS 58
7 EUROPE HYDROCEPHALUS MARKET, BY TYPE 59
7.1 OVERVIEW 60
7.2 CONGENITAL HYDROCEPHALUS 63
7.3 ACQUIRED HYDROCEPHALUS 63
7.4 NORMAL-PRESSURE HYDROCEPHALUS 64
7.5 EX-VACUO HYDROCEPHALUS 64
8 EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSTICS & TREATMENT 65
8.1 OVERVIEW 66
8.2 DIAGNOSTICS 69
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 69
8.2.2 CT SCAN – HEAD 69
8.2.3 HEAD ULTRASOUND 70
8.3 TREATMENT 70
8.3.1 SURGERY – SHUNT INSERTION, BY PRODUCT TYPE 71
8.3.1.1 HYDROCEPHALUS VALVES 71
8.3.1.2 HYDROCEPHALUS CATHETERS 71
8.3.1.2.1 ADJUSTABLE PRESSURE VALVES 71
8.3.1.2.2 FIX PRESSURE VALVES 72
8.3.2 SURGERY – SHUNT INSERTION, BY AGE GROUP 72
8.3.2.1 PEDIATRIC 72
8.3.2.2 ADULT 72
8.3.3 VENTRICULOSTOMY 72
8.3.4 MEDICATION 72
8.3.5 TREATMENT, BY AGE GROUP 73
8.3.6 INFANTS 73
8.3.7 CHILDREN 73
8.3.8 ADULTS 73
 
9 EUROPE HYDROCEPHALUS MARKET, BY END USERS 74
9.1 OVERVIEW 75
9.2 HOSPITALS 78
9.3 CLINICS 78
9.4 DIAGNOSTIC CENTERS 79
9.5 ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS 79
9.5.1 HOSPITALS 80
9.5.2 AMBULATORY AND SURGICAL CENTERS 80
9.5.3 HOSPITALS 80
9.5.4 CLINICS 80
9.5.5 DIAGNOSTIC CENTER 81
9.5.6 SURGICAL CENTERS 81
9.5.7 AMBULATORY SURGICAL CENTERS 81
9.5.8 OTHERS 81
10 EUROPE HYDROCEPHALUS MARKET, BY REGION 82
10.1 OVERVIEW 83
10.2 EUROPE 85
10.2.1 GERMANY 90
10.2.2 FRANCE 94
10.2.3 U.K. 98
10.2.4 ITALY 102
10.2.5 SPAIN 106
10.2.6 RUSSIA 110
10.2.7 TURKEY 114
10.2.8 IRELAND 118
10.2.9 BELGIUM 122
10.2.10 NETHERLANDS 126
10.2.11 SWITZERLAND 130
10.2.12 REST OF EUROPE 134
11 EUROPE HYDROCEPHALUS MARKET, COMPANY LANDSCAPE 135
11.1 COMPANY SHARE ANALYSIS: EUROPE 135
12 SWOT ANALYSIS 136
 
13 COMPANY PROFILE 137
13.1 MEDTRONIC 137
13.1.1 COMPANY SNAPSHOT 137
13.1.2 REVENUE ANALYSIS 137
13.1.3 COMPANY SHARE ANALYSIS 138
13.1.4 PRODUCT PORTFOLIO 138
13.1.5 RECENT DEVELOPMENTS 138
13.2 AESCULAP, INC. – A B. BRAUN COMPANY 139
13.2.1 COMPANY SNAPSHOT 139
13.2.2 COMPANY SHARE ANALYSIS 139
13.2.3 PRODUCT PORTFOLIO 140
13.2.4 RECENT DEVELOPMENT 140
13.3 INTEGRA LIFESCIENCES 141
13.3.1 COMPANY SNAPSHOT 141
13.3.2 REVENUE ANALYSIS 141
13.3.3 COMPANY SHARE ANALYSIS 142
13.3.4 PRODUCT PORTFOLIO 142
13.3.5 RECENT DEVELOPMENT 143
13.4 SPIEGELBERG GMBH & CO. KG 144
13.4.1 COMPANY SNAPSHOT 144
13.4.2 COMPANY SHARE ANALYSIS 144
13.4.3 PRODUCT PORTFOLIO 145
13.4.4 RECENT DEVELOPMENT 145
13.5 BICAKCILAR 146
13.5.1 COMPANY SNAPSHOT 146
13.5.2 COMPANY SHARE ANALYSIS 146
13.5.3 PRODUCT PORTFOLIO 147
13.5.4 RECENT DEVELOPMENTS 147
13.6 ANUNCIA INC 148
13.6.1 COMPANY SNAPSHOT 148
13.6.2 PRODUCT PORTFOLIO 148
13.6.3 RECENT DEVELOPMENT 148
13.7 CHRISTOPH MIETHKE GMBH & CO. KG 149
13.7.1 COMPANY SNAPSHOT 149
13.7.2 PRODUCT PORTFOLIO 149
13.7.3 RECENT DEVELOPMENT 150
 
13.8 DESU MEDICAL 151
13.8.1 COMPANY SNAPSHOT 151
13.8.2 PRODUCT PORTFOLIO 151
13.8.3 RECENT DEVELOPMENT 151
13.9 G.SURGIWEAR LTD 152
13.9.1 COMPANY SNAPSHOT 152
13.9.2 PRODUCT PORTFOLIO 152
13.9.3 RECENT DEVELOPMENT 152
13.10 HPBIO 153
13.10.1 COMPANY SNAPSHOT 153
13.10.2 PRODUCT PORTFOLIO 153
13.10.3 RECENT DEVELOPMENT 153
13.11 KANEKA MEDIX CORP 154
13.11.1 COMPANY SNAPSHOT 154
13.11.2 REVENUE ANALYSIS 154
13.11.3 PRODUCT PORTFOLIO 156
13.11.4 RECENT DEVELOPMENTS 156
13.12 KARL STORZ SE & CO. KG 157
13.12.1 COMPANY SNAPSHOT 157
13.12.2 PRODUCT PORTFOLIO 157
13.12.3 RECENT DEVELOPMENT 157
13.13 MÖLLER MEDICAL GMBH 158
13.13.1 COMPANY SNAPSHOT 158
13.13.2 PRODUCT PORTFOLIO 158
13.13.3 RECENT DEVELOPMENT 158
13.14 NATUS MEDICAL INCORPORATED 159
13.14.1 COMPANY SNAPSHOT 159
13.14.2 PRODUCT PORTFOLIO 159
13.14.3 RECENT DEVELOPMENTS 160
13.15 SOPHYSA 161
13.15.1 COMPANY SNAPSHOT 161
13.15.2 PRODUCT PORTFOLIO 161
13.15.3 RECENT DEVELOPMENTS 162
14 QUESTIONNAIRE 163
15 RELATED REPORTS 166